Prostate Cancer Screening With MRI: Lessons Learned From Repeat Rounds of the GÖTEBORG-2 and STHLM3-MRI Trials.
作者信息
Woo Sungmin, Vargas Hebert Alberto, Padhani Anwar R
机构信息
Department of Radiology, Oncologic Imaging Division, NYU Langone Health, New York, USA.
Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, United Kingdom.
出版信息
Korean J Radiol. 2024 Dec;25(12):1033-1035. doi: 10.3348/kjr.2024.1024. Epub 2024 Oct 29.
Abstract
摘要
相似文献
1
Prostate Cancer Screening With MRI: Lessons Learned From Repeat Rounds of the GÖTEBORG-2 and STHLM3-MRI Trials.使用MRI进行前列腺癌筛查：从哥德堡-2和斯德哥尔摩3-MRI试验的重复轮次中吸取的经验教训。
Korean J Radiol. 2024 Dec;25(12):1033-1035. doi: 10.3348/kjr.2024.1024. Epub 2024 Oct 29.
2
Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.PRIMA 试验结果：在未经活检的人群中，比较 STHLM3 试验和前列腺特异性抗原在一般实践中的前列腺癌检测。
Eur Urol Oncol. 2023 Oct;6(5):484-492. doi: 10.1016/j.euo.2023.07.006. Epub 2023 Aug 1.
3
Evaluating the performance of existing tools to predict clinically significant prostate cancer in men with indeterminate lesions on biparametric MRI and development of a novel multiplex model: a prospective cohort study.评估现有工具在预测双参数磁共振成像显示为不确定病变的男性中具有临床意义的前列腺癌的性能，并开发一种新型多重模型：一项前瞻性队列研究。
EClinicalMedicine. 2025 Apr 3;82:103191. doi: 10.1016/j.eclinm.2025.103191. eCollection 2025 Apr.
4
Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.基于前列腺特异性抗原检测和磁共振成像的前列腺癌重复筛查：STHLM3-MRI 随机临床试验的二次分析。
JAMA Netw Open. 2024 Feb 5;7(2):e2354577. doi: 10.1001/jamanetworkopen.2023.54577.
5
The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.哥德堡前列腺癌筛查 2 试验：一项前瞻性、随机、基于人群的前列腺癌筛查试验，采用前列腺特异性抗原检测，随后进行前列腺磁共振成像。
Scand J Urol. 2021 Apr;55(2):116-124. doi: 10.1080/21681805.2021.1881612. Epub 2021 Feb 22.
6
Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.在磁共振成像引导活检时代，使用基于血液的风险预测或前列腺特异性抗原进行重复前列腺癌筛查：STHLM3-MRI随机临床试验的二次分析
Eur Urol Oncol. 2024 Nov 18. doi: 10.1016/j.euo.2024.10.016.
7
Men's Acceptance of Screening for Prostate Cancer with Prostate-specific Antigen, Magnetic Resonance Imaging, and Prostate Biopsy.男性对前列腺特异性抗原、磁共振成像和前列腺活检筛查前列腺癌的接受度。
Eur Urol Oncol. 2024 Jun;7(3):553-562. doi: 10.1016/j.euo.2023.11.003. Epub 2023 Nov 22.
8
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.基于斯德哥尔摩3磁共振成像（STHLM3-MRI）研究的前列腺癌筛查中使用磁共振成像或标准活检的成本效益
JAMA Oncol. 2022 Nov 10;9(1):88-94. doi: 10.1001/jamaoncol.2022.5252.
9
Results after Four Years of Screening for Prostate Cancer with PSA and MRI.PSA 和 MRI 筛查前列腺癌四年后的结果。
N Engl J Med. 2024 Sep 26;391(12):1083-1095. doi: 10.1056/NEJMoa2406050.
10
Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.磁共振成像在前列腺癌筛查中的作用：哥德堡随机筛查试验中的一项试点研究
Eur Urol. 2016 Oct;70(4):566-573. doi: 10.1016/j.eururo.2015.12.006. Epub 2015 Dec 24.
本文引用的文献
1
Results after Four Years of Screening for Prostate Cancer with PSA and MRI.PSA 和 MRI 筛查前列腺癌四年后的结果。
N Engl J Med. 2024 Sep 26;391(12):1083-1095. doi: 10.1056/NEJMoa2406050.
2
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.前列腺癌筛查用 PSA、激肽释放酶组和 MRI：ProScreen 随机试验。
JAMA. 2024 May 7;331(17):1452-1459. doi: 10.1001/jama.2024.3841.
3
Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.基于前列腺特异性抗原检测和磁共振成像的前列腺癌重复筛查：STHLM3-MRI 随机临床试验的二次分析。
JAMA Netw Open. 2024 Feb 5;7(2):e2354577. doi: 10.1001/jamanetworkopen.2023.54577.
4
Prevalent vs Incident Screen: Why Does It Matter?普遍筛查与新发筛查：为什么重要？
J Breast Imaging. 2024 May 27;6(3):232-237. doi: 10.1093/jbi/wbad096.
5
Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.基于人群的有组织前列腺癌检测：对50岁男性首次邀请检测的结果
Eur Urol. 2024 Mar;85(3):207-214. doi: 10.1016/j.eururo.2023.11.013. Epub 2023 Dec 1.
6
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.45 岁时前列腺癌筛查的多参数磁共振成像：PROBASE 试验首轮筛查结果。
Eur Urol. 2024 Feb;85(2):105-111. doi: 10.1016/j.eururo.2023.09.027. Epub 2023 Oct 18.
7
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.欧盟的前列腺癌早期检测：与 PRAISE-U 联合力量。
Eur Urol. 2023 Dec;84(6):519-522. doi: 10.1016/j.eururo.2023.08.002. Epub 2023 Sep 12.
8
Prostate cancer screening-stepping forward with MRI.前列腺癌筛查——磁共振成像的进步。
Eur Radiol. 2023 Oct;33(10):6670-6676. doi: 10.1007/s00330-023-09673-2. Epub 2023 May 8.
9
An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.采用磁共振成像与前列腺特异性抗原联合检测的筛查途径评估：来自 IP1-PROSTAGRAM 研究的结果。
Eur Urol Oncol. 2023 Jun;6(3):295-302. doi: 10.1016/j.euo.2023.03.009. Epub 2023 Apr 18.
10
Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.磁共振成像用于前列腺癌筛查：哥德堡前列腺癌筛查2试验第二轮结果
Eur Urol Oncol. 2022 Feb;5(1):54-60. doi: 10.1016/j.euo.2021.09.001. Epub 2021 Sep 25.
Zotero 插件